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Abstract
Background: Tissue microarrays (TMAs) are used to study genomics and proteomics in several
tumour tissue samples. Cell lines (CC) are of great importance in the study of the genetic changes
in tumours, and some reveal several aspects of tumour oncogenesis. There are few published
reports on Ewing's tumours with TMAs including original tumours (OT) and corresponding CC.
Methods: We have performed four TMAs, from 3 OT and the corresponding CC of successive
in vivo and in vitro tumour passages. Xenotransplant CC in nude mice from OT (XT/OT) was
made. Subsequently multiple XT were performed and in vitro XT cell line (CC/XT) was obtained.
In vivo re-inoculation of CC/XT (XT/CC) was planned. TMAs with the successive tumour passages
that grew in nude mice (XT/OT and XT/CC) were analyzed by morphologic pattern (Hematoxilin/
eosin), immunohistochemical staining (CD99, FLI1, p16, p53, ki-67), fluorescent in situ
hybridization-FISH-(EWSR1 break apart, p16 and p53 status) and gene fusion types.
Results: Heterogeneous results of the p16, p53 and ki67 in OT, XT/OT, CC/XT and XT/CC were
observed. The three cell lines revealed EWS/FLI1 rearrangements. p16 gene was deleted only in
one case. The deletion was detected by FISH and confirmed by PCR assays. A p53 alteration was
found in the second case with monosomy and subsequently polysomic status of chromosome 17
during the evolution of CC. The PCR study revealed p53 mutation. The third case showed
hypermethylation in the promoter of p16. The growth of the tumour in nude mice was more
accelerated when the inoculation was performed from the CC/XT, increasing progressively over
the passages. The third case did not reveal tumour growth in nude mice after the re-inoculation of
CC/XT.
Conclusion: The study of several cores from original tumours and successive tumour passages in
TMAs facilitated the analysis of the genetic alteration and protein expression in Ewing's tumours.
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Introduction
Tissue microarrays (TMAs) are becoming the standard for
the validation of prognostic biomarkers; this new technol-
ogy leads to savings of time, cost and tissues [1]. TMAs
consist of arrays of miniature core biopsy from several
paraffin embedded tissue samples arrayed on a micro-
scope slide, and are used to assess histopathological fea-
tures, protein expression and fluorescent in situ
hybridization (FISH) analysis [2-5]. There are few pub-
lished reports on Ewing's sarcoma family tumours (ESFT)
with TMAs including original tumours (OT) and corre-
sponding xenograft and cell lines (CC).
ESFT is comprised of highly malignant bone and soft tis-
sue tumours in children and young adults [6]. ESFT shares
a common underlying molecular pathogenesis consisting
of chromosomal translocations involving the EWS gene
and one of the members of the ETS family of transcription
factors. The best approach in ESFT is based in the integra-
tion of clinical data, histopathology, immunohistochem-
istry (IHC), electron microscopy, FISH and molecular
diagnostic technologies [6-10]. The CC is of great signifi-
cance in the study of the principal aspects of the tumour
oncogenesis and in several cases is able to reveal the
genetic changes of these tumours [11,12]. Several ESFT
cell lines are available and they have been established and
characterized using cytogenetic and molecular biology
studies isolated usually from the OT and on a few occa-
sions from the in vivo and in vitro CC cultures [11,12].
The aims of this report are the analysis of p16 and p53 of
three Ewing's cell lines using TMA assays, and the possible
relation between p16 and p53 alterations and growth
velocity (Ki-67) of xenotransplanted tumours (XT): origi-
nal tumour xenotransplants and in vitro culture xenograft.
Materials and methods
Samples sources
The clinical data of the three patients are show in Table 1.
Methodology
Initially, in vivo cell culture (xenotransplant from original
tumour-XT/OT) was performed. Subsequently multiple
xenotransplanted were performed and XT tumour cell line
in vitro (CC/XT) was obtained. OT, XT/OT and CC/XT
were analyzed and characterized by morphologic pattern,
IHC, FISH and gene fusion types. Subsequently, in vivo re-
inoculation of these cell lines in nude mice (XT/CC) was
performed and all studies were made.
Assembly of TMA
Four TMAs were constructed; three included OT and the
corresponding XT. The passages in nude mice were
divided into initial (passages 1–7), middle (passages
8–16) and final (passages 20–30) to group the his-
topathological and IHC features of the XT. The last TMA
was performed with tumours from XT/CC, in these cases
the passages were divided into initial (passages 1–5), mid-
dle (passages 6–10) and final (passages 11–16). TMA con-
struction was performed as described previously [13,14].
Immunohisto-cytochemical analysis
IHC analysis was performed using anti-CD99 antibody
(clone 12E7, DakoCytomation) at a 1:50 dilution, anti-
p16 antibody (clone F12, Santa Cruz Biotechnology,
Santa Cruz, CA) at 1:100 dilution, anti-p53 antibody
(clone DO7, Novocastra) at 1:50 dilution, anti-Ki-67 anti-
body (MIB-1, DakoCytomation) at 1:50 dilution, anti-
FLI-1 polyclonal antibody at 1:25 dilution, the rest of
methodology was performed as described [13]. The
nuclear staining was considered positive for p53, p16, Ki-
67 and FLI-1 antibodies, cytoplasmic staining was not
scored as a positive phenotype. Sections were examined
and immunoreactivity was defined as follow: (-): <5%;
(+): 5% to 10%; (++):10% to 50%; (+++): >50%.
Xenotransplant
Male nude mice, were purchase from IFFA-CREDO (Lyon,
France), kept under specific pathogen-free medium
throughout the experiment, and provided with vinyl iso-
lates plus sterilized food, water, cage and bedding. The
specimens for xenotransplant were obtained at surgery
(OT) and placed in (RPMI 1640) medium plus antibiotic
at 37  until transplantation, frequent 6 hours after surgery.
Fragments of non-necrotic tumour about 3 to 5 mm in
size were transplanted into the subcutaneous tissue in the
backs of the nude mice (XT/OT). The new tumour trans-
fers were made by following the same procedure as in the
initial xenotransplant as previously described [13], and
always under highly sterile conditions. Two animals were
Table 1: Clinical data.
URE RA (PT 455) SAN VI (PT450) PAD AN (PT 445)
Age/Sex 17 years/Male 15 years/Male 16 years/Male
PrimarySite Right Scapula Dorsal Raquis Maleolar region of left foot
Recurrence no yes multiple
Metastasis yes (liver and lung) no yes (lung)
Treatment Surg+Chemo+Radio Surg+Chemo+Radio Surg+Chemo+Radio
Status Died Died DiedDiagnostic Pathology 2008, 3:S27 http://www.diagnosticpathology.org/content/3/S1/S27
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used in each passage. Materials from different passages
were obtained in order to perform all TMAs.
Cultures and cytogenetic studies
In order to perform in vitro CC as well as cytogenetic anal-
ysis, the OT and XT/OT were placed in RPMI 1640
medium at 4 , immediately after removal from the patient
or from the nude mice, and transferred to the molecular
pathology laboratory as soon as possible. The material
was cultured as previously described [10-12].
FISH analysis
Section were processed for FISH using the EWSR1
(22q12) dual colour (red-green), break apart probe
(Vysis), p16 (CDKN2A) gene specific probe (9p21-red)/
abl gene (9q34) (green) as control and p53 gene specific
probe (red)/MPO gene (17q23) green as control. FISH
was performed according to the conventional protocol for
cytology preparation and paraffin tumour[13,14]. At least
100 non-overlapping tumour cells were evaluated for
each hybridization for three different authors (RN, IM and
MP). Cells with presence of translocation involving EWS,
one fused or very near (red-green) signal and the other sig-
nals split into one green and one red signal will be
observed. In normal cells with no translocation, two fused
or very near (red-green) signal will be expected. A positive
result was defined as more than 15–20% of cells with
translocation. In the case of p16 analysis the results will be
according to the following criteria: no deletion (cells with
the same number of red and green signals), gain (cells
with more red signals than green signals), homozygous
deletion (cells with 2 green signals and no red signals),
heterozygous deletion (cells with 2 green signals and 1 red
signal), and heterozygous/homozygous deletion (combi-
nation of cells with 2 green signals and not red signals
plus cells with 2 green signals and 1 red signal). The
remaining signal combinations in cells represent a possi-
ble cut nuclei artefact. A positive result was defined as
more than 15% of cells having deletions. In case of met-
aphases from in vitro CC the aberrations were easily
detected.
Molecular biology
We performed RT-PCR on tumours to assess the presence
of EWS/FLI-1, EWS/FEV, EWS/ERG fusion products as
well as p16 and p53 status according to standard proto-
cols [10,13,14].
Results
CD99 and FLI-1 expression was strong (+++) in all sam-
ples. FISH analysis revealed a positive translocation (EWS
break apart) in the three cells lines and the fusion genes
was EWS/FLI-1 in all the cases. The immunohisto-cyto-
chemical, FISH results, and PCR study of p16 and p53 in
OT, XT/OT, CC/XT and XT/CC as well as proliferation
index (KI-67) are as follows:
First case (Table 2)
The histopathological diagnosis of OT was atyical Ewing
sarcoma with large cells, p16 IHC staining revealed strong
positivity and by FISH heterozygous/homozygous dele-
tion. PCR study confirmed p16 deletion. p53 was negative
by IHC and FISH showed neither deletion nor polysomy.
XT/OT and CC/XT maintained the same characteristics of
OT concerning p16 and p53 expression as well as FISH
results. Nevertheless in XT/CC, p53 expression was
strongly positive and the percentage of p16-deleted cells
was higher than in OT and all other samples. The growth
velocity of nude tumour was higher after the re-inocula-
tion (XT/CC) and the proliferation index (Ki-67) expres-
sion in XT/OT was negative.
Second case (Table 3)
The histopathological diagnosis of OT was classical Ewing
sarcoma, p16 IHC staining was negative and by FISH
revealed no deletion. p53 was negative by IHC and FISH
showed no deletion but did show monosomy. PCR study
revealed a mutation in p53 gene. XT/OT showed no vari-
ation in p16 expression, although p53 expression was
moderately positive (++) and p53 polysomy was detected
by FISH. p16 FISH study was similar in CC/XT and XT/CC
but p53 expression was higher with more polysomy of
chromosome 17 detected by FISH. The growth velocity of
Table 2: PT455
Sample IHC p16 FISH p16 PCR p16 IHC p53 FISH p53 PCR p53 Ki-67
OT +++ Hm/Ht deletion 2:0(25%), 
2:1(25%)
P16-1 and P16-2 deleted - No deletion No mutation -
XT/OT (Nu199) 
(P1–P7)
+++ Hm/Ht deletion 2:0(25%), 
2:1(20%)
- No deletion -
(P8–P16) +++ Hm/Ht deletion 2:1(60%) - No deletion No mutation -
(P20–P30) +++ NV - No deletion -
CC/XT +++ Hm/Ht deletion 2:1(80%) - No deletion -
XT/CC (Nu432) 
(P1–P5)
+++ Hm/Ht deletion 2:0(60%) ++ No deletion +++
(P6–P10) +++ Hm/Ht deletion 2:0(85%) ++ No deletion +++
(P11, P13–P16) +++ Hm/Ht deletion 2:0(90%) +++ No deletion +++Diagnostic Pathology 2008, 3:S27 http://www.diagnosticpathology.org/content/3/S1/S27
Page 4 of 5
(page number not for citation purposes)
nude tumour was higher after the re-inoculation (XT/CC);
the proliferation index (Ki-67) expression in XT/OT was
weakly positive and very high in XT/CC.
Third case (Table 4)
The histopathological diagnosis of OT was atypical Ewing
sarcoma. p16 and p53 showed no deletion neither polys-
omy by FISH in OT, XT/OT and CC/XT. PCR revealed p16
methylation and no alteration in p53. After re-inoculation
(XT/CC) the tumour did not grow in nude.
Discussion
Many research laboratories are taking great advantage of
TMAs in biomarker validations and study of the biology
of several tumours, furthermore, TMAs enable the preser-
vation of tissue banks and their construction is not diffi-
cult. Currently, TMAs are becoming as indispensable tool
for translating laboratory findings to the clinic [1-3,15]. In
vivo and in vitro Ewing's cell lines remain an invaluable
research tool in the study of the multistep progression of
ESFT. The combination of TMAs, xenograft in nude mice
and in vitro cell line studies in ESFT enable researchers to
determine the clinical significance of specific morpholog-
ical and protein alterations in several tumours samples
and facilitate a comparison of protein expression and his-
topathological variation in successive tumours passages
[5,13,14]. The analysis of OT and xenograft tumours were
performed using TMA analysis in order to discover the var-
iations in histopathological, tumour heterogeneity and
progression, and immunohistochemical profile. We study
the expression profile using triplicate tissue cores because
they offer a high concordance rate with whole sections.
Several studies on tumour progression in different
tumours and cell lines using TMAs have been published
[13,16] but there are few studies involving TMAs, cell lines
and xenografts in ESFT. The clinical data in the three cases
were similar with scant variation as the ESFT cases
described in the literature [6,10,17]. Morphologically, the
most interesting change was the transition of most of the
primary tumours to a more undifferentiated tumour in
the xenograft similar to the features described by other
authors in sarcoma xenograft study [13,16], although the
IHC profile revealed strong expression of CD99 and FLI-1
antibodies in all the OT, cell lines and most of the
xenotransplanted tumour. A slight decrease in CD99
expression was observed in terminal passages in xenograft
but was not significant. EWS break-apart was positive as a
reflex of EWS/FLI-1 gene fusion as the most frequent
genetic aberration described in ESFT [6,10,12,18,19]. p16
and p53 alterations are reported to be important in
tumour progression, both are the most frequent altera-
tions relate to cancer [8,12,20-26]. Hypermethylation is a
powerful mechanism for the silencing of tumour suppres-
sor genes in cancer, but intriguingly, only the two cases
with genetic alteration developed growth in nude after re-
inoculation of XT/CC, the case with epigenetic alteration
did no grow in nude after re-inoculation. The high index
of growth in XT/CC could be related with a higher per-
centage of cells with genetic and/or epigenetic alterations.
The stroma cells or necrotic cells in OT could limit the
velocity of growth of the tumour in nude after xenograft.
Therefore, in culture, Ewing's tumour cells grow very fast
Table 3: PT450
Sample IHC p16 FISH p16 PCR p16 IHC p53 FISH p53 PCR p53 Ki-67
OT - No deletion normal - Monosomy Mutation 151:CCC/CGC 
Prox/Arg
+
XT/OT (Nu267) (P1–P7) - No deletion ++ Polysomy 3:3(70%) +
CC/XT - No deletion +++ Polysomy 3:3(75%) +
XT/CC (Nu416) (P1–P5) 3+ No deletion +++ Polysomy ++ 3:3(80%), 4:4, 
6:6 (5%)
+++
(P6–P8) 3+ No deletion +++ Polysomy ++ 3:3(85%), 4:4, 
6:6 (5%)
+++
(P9–P11) 3+ No deletion +++ Polysomy +++ 3:3(85%), 4:4, 
6:6 (15%)
+++
Table 4: PT445
Sample IHC p16 FISH p16 PCR p16 IHC p53 FISH p53 PCR p53 Ki-67
OT +++ No deletion Methylation altered - No deletion No mutation -
XT/OT (Nu22) (P1–P7) ++ No deletion + No deletion -
(P8–P16) +++ No deletion + No deletion -
(P20–P30) - NV + No deletion -
CC/XT -N o  d e l e t i o n - N V -
XT/CC (Nu441) No growth No growth No growth No growth No growth No growth No growthDiagnostic Pathology 2008, 3:S27 http://www.diagnosticpathology.org/content/3/S1/S27
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and replace stroma and necrotic cells, then after inocula-
tion from cell culture, the possibility of growth in nude is
higher. The tumour cells in culture could acquire new
genetic alterations and/or aberrant protein expressions
that improved the aggressive phenotype. In fact our XT/
CC showed new aberrant p16 and p53 expression as well
as increased genetic alterations. Milne AN et al. [16],
described recently that epigenetic changes may represent
alterations present in more aggressive subclones or could
be induced during tumour progression or cell lines estab-
lishment.
Conclusion
The use of TMA-based morphological and immunohisto-
chemical evaluation of Ewing's sarcoma proved to be an
important tool in demonstrating the phenotypic varia-
tions of xenografted Ewing's sarcoma. The implementa-
tion and analysis of several cores in OT and successive
passages from xenograft enable us to describe the histopa-
thology and phenotypic variations in theses tumours sam-
ples.
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